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The purpose of this study wu to evaluate the iD vivo 
effect of FK506 on human pancreatic isiets. Twenty-
five Dude mice were made diabetic by one iDtraveDous 
injection of streptozotociD. Approximately 600 islets 
were admiDistered iD the renal subea~ular space 3-5 
days followiDg streptozotociD admiDistratioD. ODe week 
..cter traDsplaDtatioD, the mice were divided iD four 
groups. ID group 1. the lUlimals received 1 injectioD of 
0.6 ml of dilueDt i.p. daily for one week. ID groups 2. 3. 
Uld 4 the treatmeDts were daily i.p. iDjectioD of 0.3. 1. 
and 3 mil kg FK506. respectively. After treatment, the 
rUDctional iDtegrity of the trlUllPllUlted humaD islets 
wu tested by meuuriDg the pluma glucose and humaD 
C·peptide response to iDtraperitoneal gluCOBe injection 
in groups 1 and 4. IPGTT aloDe wu aueaed in groups 
2 and 3. The renits iDdicate that i.p. admiDistration of 
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FK508 (or one week at a dose 0.3 mg/kg/day did not 
result in any significant aiteration of glucose disappear-
ance and C-peptide response to IPGTT. Higher doaes of 
FK506 produced a significant delay in gluCOBe disap-
pearance in groups 3 and 4. and a 8ignificant inhibition 
of glucose-mediated C-peptide response iD group 4 . 
FK506 has recently joined the growing list of new pharma-
ceuticals with potent immunosuppressive properties ( 1). Post· 
tranaplant hyperglycemia is a well recognized side effect of 
moat standard immunosuppressive drugs, including prednisone 
(2) and cyclosporine A (3-5). which are known to be diabeto-
genic in men. Similar effecta have been ascribed to FK506 in 
both experimental (6. 7) and clinical studies (8). As clinical 
experience is successfully extended. there wlil be new applica-
tiona for the drug besides whole organ transplantation. FK506 
haa been recently used as a main immunosuppresaive agent in 
clinical trials of islet transplantation «9\. In addition. interven-
tion triala of FK506 in the treatment of newoOnset type I 
diabetes mellitus are planned. The aim of this atudy was to teat 
the in vivo effect of FK506 on human pancreatic isleta. 
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MATERIALS AND METHODS 
HwnIJI& Ltlet iaoiatiDn. Human illeta were prepand from c:adaver 
donor panc:re .... obtained from muitiorpD donora UO, 11). After in 
litu perfusion of the abdominal aorta with 1500-2000 mJ of University 
of Wiac:onsin solution (UW) additional 500-1000 ml of UW was infused 
direc:tiy into the liver via the portal vein. Venous hypertension of the 
pauc:rea "'a avoided by venting the portal andlor spleniC: vein. The 
pauc:rea ",al immersed in UW and packed in ice until the islet isolation 
began. The isleta were isolated.. previously described (9, 12). Briefiy, 
after intraduc:tal injection of 350 ml of Hanb' solution containing 2 
ml/mJ collqenae (Boehrinpr-MlDDheim. type P) the pauerea "'. 
loaded into a ItaiDleu lteel dipetion chamber and the isleta were 
separated. durin( a conUnuoua d.ipetion proc:etl that lasted 40-50 min 
(12). The isleta were purified by cenuifuption on Euroc:olliDa-Ficoll 
grad.ienta (denaity - 1.108. 1.096, 1.037) using a COBE 2991 cell 
separator (COBE Laboratories. Lakewood. CO) (9). 
AninacUa. Mala BALBlc nude mice (16-20 g body ",eight) were used 
a illet recipienta. The anima.Ia were made diabetic by one intravenoua 
injection of ItreptozotociD (165 me/kr). 
HwnIJI& Ltlec t~nK Only mice with nonfaating pluma 
glUCOle >400 mg/cIl were used a recipienta of hWIWI isletl. Each 
IDima.I received an aliquot of approzimately 600 human ialm of 150-,. 
diameter (13) 3-6 da" after .treptozotoc:iD administration. The weta 
were transplanted. beneath the left renal capluie a previously described 
(14). 
Treatment. FK506 (10 mg) "'. diuolved in a minure of cremaphor 
(625 mg) and ethanol (328 mg). This solution ",a diluted with norma! 
aaline to give a concentration of 100 mg/ml. The aaline solution of 
FK506 "'. prepared fresh daily for injection. 
One week after hWIWI iaIet transplantation the animaia were divided 
in four groups. In group 1 (n-10). the animaIa received one injection 
of 0.5 ml of c:remaphor-ethauol-u.line (without FK506) i.p. daily for 
on. week. In group 2 (n-6) the anima.Ia were treated by daily i.p. 
injection of 0.3 mllkr FK506, ",hile in groupa 3 (n-6) and 4 (n-6) the 
daily injectiona were 1 and 3 mg/k, FK506, reapectively. 
InlIaperitDrwal ,iuI:oIe tDleratU:e te,t, At 15 da" after illet trans-
plantation. the animala underwent IPGTT CIS). The animaIa ",ere 
futed overnight (18 hr) and then injected inUaperitoneally ",ith 25'" 
glUCOlland 0.9'" sodium c:hloride solution (2, rlucoN/kg body weight). 
Blood IlUDple. were obtained before (0 min) and 15, 30, and 60 min 
after gluc:oN injection and analyzed for plama IluCOll and human C-
peptide levelL 
PWmtJ ,tucoae and hwnlJl& C·peptVJ. determination. Whole-blood 
(100 1&1) "'. collected into mic:rohematocrit capillary tubea and placed 
on ice. Plume "'. prepared by centrifu.ation at 10.000 xg for 3 min 
in a mic:roc:entrifup, and pluma IIUCOIe w. meuured with Beeman 
GIUCOll Analyzer II (Fullerton. CAl. Blood l/UDPI .. for human C-
peptide determination were collected. previously detcribed for aerum 
inau1in (16). C-peptide ",a analyzed oniy in groupe 1 and 4. A 20-,.1 
sample of blood wu diluted in 200 ,.1 of aaline, and the Nrum aeparated 
and .tored at -20°C until radioimmunouaay. Human C·peptide "'" 
.... yeci by a double-antibody 1:111 radioimmunouaay (17). The human 
C·pepude ltandud solutiona and the rabbit antihuman C-peptide 
(serum K6) ",ere obtained from NOVO Biolabe (Danbury, CT). Th. 
human mono I_J Tyr·C-pepude "'" a gift from Eli Lilly and Company, 
Indiau.polia.IN. 
DetermUIGUDII of FK506 blood lewll. Immediately after IPGTT the 
animala of group 2. 3, and 4 ",ere .. c:nticed and the blood collected for 
determmation of FK506 leveia. The FK506 .... y "'u performed by the 
modified enzyme immUDouaay UB) uaiD( a mouee monoclonal anti-
FK506 antibody (Fujita..,. Pharmac:euticall Co. Ltd. Osaka. Japan). 
HiIlDIotic ItlMlia. The kidneya bearinr the human illet tranaplanta 
were elaaeci for determinatIOn of morphologic intelftty of the human 
illatl gra{u.ln group 1 (control) a nephrectomy of the kidney bearinl 
the II'8ft wu performed to demonstrate that the hWIWI IIlet traM' 
planta ",ere rnponaible for the maiDteD8DC8 of nOflllOllycemia. HiI-
tolocic intepi&y of the renal .ubcapaWar II'8ft "'u determiDad by 
b.lD8t.oaylin auG aoaiD .tam and by immUDopanmdue tiDluwd at.aiD. 
StotUtiaJlGMlyli&. All resulta are ezpreued. meana ~ SO AN 
"'U uaed to compare differences between groupa. and P v".! o\' ~ 
given. meuurea of .tatiatical aigniflCaJlCe. \III '" 
RESULTS 
The results are summarized in Tables 1 and 2 and in ci~ 
1 and 2. Intraperitoneal admin~stration o( FK506 for one ~fr 
at a dose of 0.3 mg/kg/day did not produce any 8ignific: 
lte' (I di . ant a ration 0 g ucose ssappearance after mtraperitoneal d 
ministration of glucose. Higher doses o( FK506 Produc:e: . 
significant delay in plasma glucose disappearance. In croup : 
and 4, 2 o( 10 animals demonstrated hyperglycemia befo~ 
IPGTT (futing plasma glucose >200 mgjdl).In these animala 
the presence o( fasting hyperglycemia despite normallevela of 
human C-peptide indicated that peripheral insulin resistance 
could be responsible (or the hyperglycemic effeet of FKso6 
Nevertheleaa, with high-dose treatment insulin secretion ap~ 
pearl to be impaired as well. Furthermore, 5 of 10 animal. 
remained hyperglycemic 1 hour after intraperitoneal gluc:oe. 
injection. Human C-peptide levels following IPGTT indicated 
that abnormal glucose disappearance in group " was asaociated 
TABU 1. Intraperitoneal,lucoee tolerance teat-plume ,IIICOII 
(mg/cil)" 
Group o· 1Ii" 30' 60" 
1 62.6:12.9 OU9KU~TTKR 1RSKS~1lM •• SSKT~1SKR 
2 SRKS~49KU 296.0:5'" 11402:45.8 70.8:tlU 
3 96.8:61.2 P4r~TMKO O1TKM~1PPKU 168.2%140.1 
.. 92.8:t90.1 .47.0±&U P1MKU~19UK9 OP9KS~OMr 
• Plasma rluc:oae levela 0, 15. 30, and 60 min followin,an intrapen. 
toneai gluc:oae toleranca teat performed 15 da" after hUDI8D ia1et 
tranaplantation beneath the renal capsule of diabetic nude mice. batra. 
peritoneal adminiatration of FK506 for 1 week before the teat produceci 
a doee-dependent efrect on ,luc:oee disappearance. 
• P<O.05: 1 VI. 4: 2 VI. 4; 1 VI. 3. 
, P<O.05: 1 VI. 4. 
TABLE 2. Intraperitoneal ,Iucose toleranc:e teat-human C-pepticIe 
(pmol/mi)" 
0 15' 30' 60' 
Group 1 (control) 
1. 0.66 0.99 1.75 2.31' 
2. 1.54 3.3 4.73 2.09 
3. 1.43 2.31 3.52 2.53 
4. 1.32 1.98 4.95 2.53 
5. 0.66 1.76 1.87 1.98 
Mean 1.12 2.07" 3.36 2.2 • 
SD 0.38 0.75 1.36 0.192 
Group 4 (1 ",eek of FK506, 13 
mllkr/dayJ) 
1. 1.43 0.88 2.53 2.&& 
2. 1.21 1.1 1.1 1.98 
3. 0.99 0.88 2.53 1.21 
4. 1.21 0.77 1.1 1.1 
5. 1.65 1.43 2.53 0.68 
Mean 1.30 1.01" 1.96 1.52 
SD 0.22 0.23 0.70 0.70 
• Human c:·peptide level. 0, 15. 30. and 60 min followinl an intra· 
peritoneal Ilucoae tolerance telt. At 15 minutea after IIUCOII IIljection 
a deere ... in human c:·peptide levell ",a obaerved in animaia &reaSICi 
with bi,h doua of FK506 (group 41 that ",a lignifacauuy lower COlD' 
panel with Il'OUP 1 (control). 
• P<O.028. 
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FlOURE 1. Plasma gluCOle levels during intraperitoneal glucose tol· 
'I'IDCI telt 15 daya after human islet traDlplantatioD iD tbe renal 
lUbcapaular space of diabetic nude mice. 
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F!OURit 2. Human C·peptide levela durin( an intraperitoneal glu-
COlI tole~nce telt 15 daya after humaa III" transplantation In the 
'-Ial lubcaplular apace of diabetic nuda mice. 
with an mitial impairment of insulin secretion from the en· 
&rifted isleta. In fact. 15 min after glucose injection a decrease 
ill buman C·peptide levels wu observed in group 4. in controt 
to the control groups, in which a two fold increase in C-peptide 
.... ohserved. The difference in C-peptide level. between the 
t1to troups was statistically significant only st the 1S-min level 
(P<o.028). 
. The determination of plasma FK levels after IPGTT resulted 
1.11 an average of 3.8±2.8 ng/ml (group 2). 106.6±6.3 ng/ml 
(croup 3). and 303.S±173.7 ng/ml (group 4). 
Hiatologic studies of the renal subcapsular isleta indicated 
that human islets were present in the renal subcapsular space 
at ttl transplanted animals. Neverthelesa. in tbe 2 animals 11 
ill croup 3 and 1 in group 4) who were hyperglycemic. the beta 
ctlla appeared de~ulatedK In the remaining animals the 
t.u.an Islets appeared well·preserved. with no lignificant dif· 
_ee between FK506 treated and control animala. In group 
1 (controll a nephrectomy of the kidneyt beann, the grafts 
IItoduced a rapid retum to the diabetic ltate. indicating that 
ta. human taleta tranapluted were responsible for the main-
-... of normoglycemiL 
DISCUSSION 
This study indicates that FK506 did not produce significant 
alteration of glucose homeostasis in animals treated with a dose 
of 0.3 mg/kg/day for 7 dayt. Nevertheless. the efrecta of the 
drug on insulin secretion and glucose disappearance after in-
traperitoneal glucose have been observed at higher doses. These 
efrecta appear to be doae-dependent and are obaerved with 
serum FK506 levels that are significantly higher than thera· 
peutic levels achieved in man. Although these levels are lignif-
icantiy higher than the therapeutic levels in current use in 
patients, the potential accumulation during chronic treatment 
with the agent in the pancreas, like cyciosporine, may induce 
islet secretory defects even at therapeutic levels. In addition. 
the pharmacodynamici of FK506 may differ between the two 
species. 
These findings confirm the results of previous reports on the 
effect FK506 on rat and human islets in vitro (19). Further 
studies are needed to determine whether the toxic effect of 
FK506 observed at higher doses is reversible upon discontin-
uation of treatment. 
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